Megace

Megestrol acetate, the active ingredient in Megace, is a synthetic progestin presented as an oral tablet for oral use. It is indicated for appetite stimulation in cachexia related to AIDS or cancer and for the treatment of selected breast and endometrial cancers, and may improve quality of life.

GNH USA supplies Megace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global demand.

Megestrol acetate is used in conditions where appetite stimulation or anti‑estrogenic activity is required, particularly in cancer‑related settings. - Cachexia associated with AIDS or cancer: helps increase caloric intake, leading to weight gain and improved functional status. - Breast cancer: provides antineoplastic effect in hormone‑responsive disease, helping to control tumor progression. - Endometrial cancer: used as hormonal therapy to inhibit tumor growth and reduce disease activity.

Megestrol acetate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Weight gain: increased appetite and fluid retention. - Nausea or vomiting. - Fatigue or weakness. - Edema: swelling of the lower limbs.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Adrenal suppression: reduced cortisol production. - Hyperglycemia: elevated blood glucose levels. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

When prescribing Megestrol acetate, clinicians should consider several safety precautions to minimise risks. - Assess baseline weight and nutritional status: monitor changes during therapy. - Screen for history of thromboembolic disease: avoid use in high‑risk patients. - Monitor blood glucose: patients with diabetes may require dose adjustment. - Evaluate liver function: periodic tests are advised for hepatic safety. - Review concomitant corticosteroid use: may increase risk of adrenal suppression. - Store at ambient temperature: keep tablets below 25 °C, in the original container, protected from moisture.

Megestrol acetate can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of thrombosis. - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce megestrol levels. - Hormonal therapies (e.g., tamoxifen): antagonistic effects on anti‑estrogenic activity.

Moderate Interactions (Monitor Closely): - Glucocorticoids: additive risk of adrenal suppression. - Antidiabetic agents: potential for altered glucose control. - NSAIDs: may increase risk of gastrointestinal irritation.